IPO Details
Bidding Dates
07 Nov 25 - 11 Nov 25
Lot Size
2000
Price Range ₹
120 - 128
Exchange Status
NSE
Total Equity
₹ 28.80Cr
IPO Doc
IPO Timeline
Listing
--
Offer start
07 Nov 2025
Offer end
11 Nov 2025
Allotment
12 Nov 2025
Refund initiation
13 Nov 2025
Demat transfer
13 Nov 2025
Listing
--
Offer start
07 Nov 2025
Offer end
11 Nov 2025
Allotment
12 Nov 2025
Refund initiation
13 Nov 2025
Demat transfer
13 Nov 2025
About Company
Curis Lifesciences Ltd. is a pharmaceutical company incorporated in 2010, engaged in the development, manufacturing, and distribution of a diverse range of pharmaceutical products. The company produces tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments, serving both domestic and international markets. It operates through loan license and contract manufacturing for over 100 corporate clients and manages its own brand marketing in countries like Yemen and Kenya. Curis Lifesciences runs a state-of-the-art manufacturing facility in Sanand, Gujarat, equipped with advanced technology and strict quality control systems to ensure product safety and efficacy. With an experienced management team, scalable operations, and a wide product portfolio, the company focuses on maintaining high-quality standards and expanding its presence in global markets.
Year Founded
23-03-2016
Promotor Details
Dharmesh Dasharathbhai Patel
Promoter Holdings Details
| Particular | Pre-IPO | Post-IPO |
|---|---|---|
| Percentage | 92.68 | 0 |
| Share Capital | 500000 | 0 |
Offer to Public
22,50,000.00 Cr
Project Details
- Funding our Working Capital Requirements - 112.5cr
- Funding capital expenditure towards improvement of our - 55.103cr
- Product Registrations in other countries - 26.068cr
Objectives
- i.Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities
- ii.Capital Expenditure towards Construction of a Storage Facility
- iii.Pre-payment/Repayment of outstanding Secured Loans
- iv.Product Registrations in other countries
- v.Funding our Working Capital Requirements
- andvi.General Corporate Purpose.
Highlights
- Revenue and PAT growth of 38% and 25% respectively indicate solid business performance.
- ROE of 55.25% and ROCE of 27.83% reflect efficient use of capital.
- Covers multiple pharmaceutical categories, reducing dependency on a single product line.
- Sanand facility in Gujarat offers logistical and operational advantages.
- Combination of loan license manufacturing and brand marketing enables flexible expansion.
Challenges
- Debt-to-equity ratio of 0.96 shows moderate leverage risk.
- Own-brand marketing is still small with only 2 clients abroad.
- Over-reliance on loan license clients can affect margins if contracts shift.
- smaller market capitalization (~₹103 Cr) means higher volatility and lower liquidity post-listing.
- Lack of analyst recommendations makes valuation and growth projections uncertain.
Financials
| Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
|---|---|---|---|---|---|
| 2022 | 2,739.85 | 50.00 | 486.70 | 486.70 | 8.8491 |
| 2024 | 3,387.63 | 50.00 | 49.24 | 49.24 | 0.8953 |
| 2025 | 4,253.47 | 593.44 | 486.70 | 486.70 | 8.8491 |
| 2023 | 2,974.75 | 50.00 | 610.51 | 610.51 | 10.2876 |
